Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke.

Bohmann F, Mirceska A, Pfeilschifter J, Lindhoff-Last E, Steinmetz H, Foerch C, Pfeilschifter W.

PLoS One. 2012;7(7):e40804. doi: 10.1371/journal.pone.0040804. Epub 2012 Jul 24.

2.

Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke.

Pfeilschifter W, Bohmann F, Baumgarten P, Mittelbronn M, Pfeilschifter J, Lindhoff-Last E, Steinmetz H, Foerch C.

Ann Neurol. 2012 May;71(5):624-33. doi: 10.1002/ana.23558. Epub 2012 Mar 23.

PMID:
22447744
3.

Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia.

Sun L, Zhou W, Ploen R, Zorn M, Veltkamp R.

Thromb Haemost. 2013 Jul;110(1):153-61. doi: 10.1160/TH12-12-0942. Epub 2013 Apr 25.

PMID:
23615682
4.

Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.

Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R.

Stroke. 2011 Dec;42(12):3594-9. doi: 10.1161/STROKEAHA.111.624650. Epub 2011 Oct 13.

5.

Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: an experimental study in mice.

Gliem M, Hermsen D, van Rooijen N, Hartung HP, Jander S.

Stroke. 2012 Dec;43(12):3352-7. doi: 10.1161/STROKEAHA.112.666818. Epub 2012 Nov 1.

6.

Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.

McKellar SH, Abel S, Camp CL, Suri RM, Ereth MH, Schaff HV.

J Thorac Cardiovasc Surg. 2011 Jun;141(6):1410-6. doi: 10.1016/j.jtcvs.2011.02.011. Epub 2011 Mar 22.

7.

Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.

Kono S, Deguchi K, Omote Y, Yunoki T, Yamashita T, Kurata T, Ikeda Y, Abe K.

J Neurosci Res. 2014 Jan;92(1):46-53. doi: 10.1002/jnr.23302. Epub 2013 Nov 4.

PMID:
24265137
8.

Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice.

Davis C, Robertson C, Shivakumar S, Lee M.

J Can Dent Assoc. 2013;79:d74. Review.

9.

Warfarin anticoagulation exacerbates the risk of hemorrhagic transformation after rt-PA treatment in experimental stroke: therapeutic potential of PCC.

Pfeilschifter W, Spitzer D, Pfeilschifter J, Steinmetz H, Foerch C.

PLoS One. 2011;6(10):e26087. doi: 10.1371/journal.pone.0026087. Epub 2011 Oct 19.

10.

[Dabigatran, a new oral anticoagulant].

Uchiyama S.

Brain Nerve. 2011 Apr;63(4):411-5. Review. Japanese.

PMID:
21441645
11.

Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.

Li YZ, Gong GQ, Yang WH, Wang XH, Jiang ML, Zhou Y, Yang XZ, Xu YG, He GW.

Thromb Res. 2013 May;131(5):425-35. doi: 10.1016/j.thromres.2013.03.004. Epub 2013 Mar 25.

PMID:
23535565
12.

Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.

Schaefer JH, Leung W, Wu L, Van Cott EM, Lok J, Whalen M, van Leyen K, Lauer A, van Ryn J, Lo EH, Foerch C.

J Cereb Blood Flow Metab. 2014 May;34(5):870-5. doi: 10.1038/jcbfm.2014.31. Epub 2014 Feb 19.

13.

Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.

Lauer A, Cianchetti FA, Van Cott EM, Schlunk F, Schulz E, Pfeilschifter W, Steinmetz H, Schaffer CB, Lo EH, Foerch C.

Circulation. 2011 Oct 11;124(15):1654-62. doi: 10.1161/CIRCULATIONAHA.111.035972. Epub 2011 Sep 12.

15.

Dabigatran: a new chapter in anticoagulation.

Ahmed S, Levin V, Malacoff R, Martinez MW.

Cardiovasc Hematol Agents Med Chem. 2012 Jun;10(2):116-23. Review.

PMID:
22480286
16.

Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment.

Watanabe M, Siddiqui FM, Qureshi AI.

Neurocrit Care. 2012 Feb;16(1):203-9. doi: 10.1007/s12028-011-9591-y. Review.

PMID:
21748501
17.

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.

Clemens A, van Ryn J, Sennewald R, Yamamura N, Stangier J, Feuring M, Härtter S.

Eur J Clin Pharmacol. 2012 May;68(5):607-16. doi: 10.1007/s00228-011-1205-2. Epub 2012 Jan 18.

18.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
19.

[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].

Panchenko EP.

Kardiologiia. 2011;51(11):83-90. Review. Russian. No abstract available.

PMID:
22117775
20.

Increased risk of hemorrhagic transformation in ischemic stroke occurring during warfarin anticoagulation: an experimental study in mice.

Pfeilschifter W, Spitzer D, Czech-Zechmeister B, Steinmetz H, Foerch C.

Stroke. 2011 Apr;42(4):1116-21. doi: 10.1161/STROKEAHA.110.604652. Epub 2011 Feb 17.

Items per page

Supplemental Content

Write to the Help Desk